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1. Introduction  
1.1 Defining differentiation and cell fate in cancer 
In the setting of embryonic development, terms such as “cell fate“ and “cellular 
differentiation“ are relatively easy to grasp, since they refer to a straightforward linear 
model whereby progenitor cells give rise sequentially to various distinct and identifiable 
lineages, eventually resulting in a terminally differentiated cell that has until recently been 
thought to possess very little cellular plasticity or multipotent capacity. The sequences of 
events that regulate this process are extremely well conserved within a species, and even 
across species in many instances. In the setting of cancer, cell fate and cellular differentiation 
are often used descriptively to convey an observed phenotype rather than a defined and 
well-understood molecular process. How accurate is it to refer to “differentiation“ in cancer 
when the so-called end-point for this process results in cellular heterogeneity that is 
antithetical to the regulated and predictable differentiated cells that result from embryonic 
development? What does it mean to refer to “cell fate“ during the inherently dysregulated 
series of events involved in oncogenesis, which may not result in a distinct endpoint even 
across cells within the same tumor?   
Our review uses these terms in reference to the dynamic processes that constantly shape the 
function and properties of melanoma cells, which coincidentally utilize many of the same 
pathways involved in the regulated process of differentiation and determination of cell fate 
during embryonic development. While the label of being a differentiated cell may imply a 
terminal nature that might be viewed as less tumorigenic or lethal in the setting of cancer, this 
concept requires further experimental confirmation. Undoubtedly, these terms will become 
more refined as our understanding of the molecular events underlying melanoma progression 
comes into clearer focus. For now, they are the best terms available to describe some of the 
events and processes that help determine the behavior and response of tumor cells, and we use 
them with the full knowledge that years from now, advances in our understanding of cancer 
could render these terms woefully inadequate, or worse yet inaccurate. 
1.2 Differentiation in nevi and melanomas 
At one time, the classification of melanomas at the cellular level was largely limited to cell 
morphology, the expression profile of selected melanocytic or neuronal markers by 
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immunohistochemistry, and the presence or absence of phenotypic characteristics such as 
pigmentation. These early clinical and histological observations provide relevant insight into 
the role of cellular differentiation in both benign nevi and in melanoma (Barnhill et al., 2004). 
The phenomenon of “maturation with depth“ was described histologically in nevi well before 
the advent of molecular genetics (Winkelmann and Rocha, 1962), and highlights the capacity 
of certain nevus cells to dynamically evolve and undergo changes in cell fate, either through 
autologous signaling or in response to stromal factors. Maturation with depth is also seen in 
certain subsets of melanomas (sometimes termed “nevoid melanomas“), which reflects some 
of the cellular and molecular plasticity seen across tumors (Schmoeckel et al., 1985).  
Within the past decade, the sequencing of the human genome and the rapid development of 
technologies such as microarrays and deep sequencing has markedly advanced our 
understanding of cellular transcriptomes and led to the use of gene expression signatures as 
indicators of cell fate and cellular differentiation. It has become increasingly clear from 
studies in melanoma and across all cancers that the gene expression profile of a tumor or cell 
line can provide important information regarding the origin of the cancer cells, the status of 
various signal transduction pathways, and even the potential therapeutic susceptibility of 
cells to specific therapies. Furthermore, these analytic advances have confirmed the 
heterogeneity of melanoma that was already well-described histologically. 
1.3 Objectives 
Because cellular phenotype represents a primary measure of the state of melanoma cell 
differentiation, the focus of our discussion will center on some of the accumulated data 
regarding the characterization of phenotype by various experimental measures. Our overall 
goal is to summarize the literature on  differentiation and cell fate in melanoma, focusing on 
the gene expression profiles of both proliferative as well as invasive melanoma cells, along 
with discussing the mechanisms by which these profiles result in the described phenotypes. 
We will also review how gene signatures relate to the dynamic process of cellular 
differentiation in melanoma cells, including the evidence for the existence of phenotype 
switching, and how this phenomena may contribute to melanoma heterogeneity. Finally, we 
will examine how genetic mutations, phenotypic instability and therapeutic susceptibility 
affect efforts to treat this deadly disease. In the end, we hope that this review will stimulate 
thought and discussion on the viability of directed differentiation in melanoma and other 
cancers as a potential therapeutic strategy. By exploiting the powerful regulatory effects of 
the morphogen pathways utilized by cancer cells during oncogenesis, these types of 
strategies could potentially alter not only the behavior of these cells, but also their 
susceptibility and response to current and emerging cancer therapies. 
2. Global genetic regulation of melanoma differentiation 
2.1 Historical observations and recent advances 
2.1.1 The challenge of melanoma treatment 
Melanoma is the most lethal form of skin cancer, and both the incidence and consequent 
mortality rates of this deadly disease have increased globally in recent decades (Lens and 
Dawes, 2004). Death from this cutaneous neoplasm usually occurs as a result of distant 
metastasis, most commonly affecting the lungs, liver and brain. Its ability to become 
invasive and metastasize within months of the initial lesion developing makes melanoma 
one of the most aggressive forms of all human cancers (Miller and Mihm, 2006). Recent 
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advances in radio-, chemo- and immunotherapies have resulted in improved prognoses and 
prolonged survival times in many different types of malignancies.  Melanoma however, has 
remained largely resistant to treatment by any combination of these three therapeutic 
modalities, with current cancer treatment options still resulting in a median survival time of 
12 months or less in patients diagnosed with metastatic disease (Tsao et al., 2004). 
2.1.2 The intersection between developmental biology and cancer 
In recent years, we have gained a deeper understanding of the mechanisms underlying 
melanoma progression from a primary melanocyte to metastatic disease. Classically, this 
transformation has been viewed as the step-wise accumulation of genetic and epigenetic 
aberrations which results in an increasingly more malignant phenotype (Singh et al., 2008). 
A key feature of this progression model is the explicitly one-way nature of gene mutation. 
Based on this view of melanoma progression, a theory reminiscent of Darwinian natural 
selection has been conceived to explain the inevitable development of cellular heterogeneity 
and therapeutic resistance in melanoma tumors. Specifically, it is commonly believed that 
melanoma cells are constantly accumulating novel, prometastatic genetic mutations, which 
inevitably lead to the development of dominant subpopulations of tumor cells with a 
distinct survival advantage. As new dominant subpopulations are generated from ongoing 
genomic instability, the constantly evolving tumor is able to both maintain cellular 
heterogeneity, as well as develop dynamic resistance to chemotherapeutic agents.  
As tumor cells acquire more mutations, their properties dynamically change, as measured 
by changes in global gene expression or by changes in their capacity for relevant functions 
such as motility, proliferation, or invasion. By convention, these changes in cellular 
phenotype define a new cell fate, and reflect a process of differentiation (albeit 
dysregulated) that parallels the observed maturation of non-cancerous cells during 
development. To appreciate concepts such as differentiation and cell fate in the 
dysregulated setting of melanoma, one needs to have some contextual understanding of 
differentiation and cell fate determination in the normal development of cells that may serve 
as precursors for this deadly cancer. While the cell of origin for melanoma is almost 
certainly of neural crest origin, and likely in the melanocytic lineage, the recent unexpected 
finding that murine epidermal melanocytes can arise from a niche of Schwann cell 
precursors highlights the incomplete nature of our current understanding (Adameyko et al., 
2009). This finding suggests that an understanding of Schwann cell biology could be 
potentially relevant for identifying and treating melanomas that may arise from this distinct 
precursor population, since these melanomas could conceivably display different cellular 
phenotypes than melanomas derived from non-Schwann cell-derived melanocytes.  
While previous models of development have depicted differentiation as primarily a one-
way event, the observation that differentiated Schwann cells can be induced to form 
progenitor cells that subsequently give rise to glia and melanocytes provides evidence that 
so-called “terminal differentiation” does not preclude the ability to acquire pluripotency 
and/or the initiation of broad changes in cellular programming (Dupin et al., 2003). 
Likewise, the observation that melanocytes can de-differentiate to a precursor cell that gives 
rise to mature glia (Dupin et al., 2000) may further reflect a plasticity or instability of cell fate 
that is fundamentally relevant for melanoma and the exceptional resistance of this cancer to 
treatment.  
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2.1.3 Insight from gene expression profiling studies 
An emerging body of evidence is re-defining the conventional genetic model of melanoma 
progression. Gene expression profiling studies using multi-center cohorts of patient tumors 
have previously revealed the existence of two major expression signatures (Hoek, 2007; 
Hoek et al., 2006). These signatures correlate to two distinct populations of melanoma cells, 
one with a predominantly proliferative phenotype and the other with a predominantly 
invasive phenotype. Subsequent transcriptional profiling studies in melanoma cells have 
revealed two discrete states of differentiation (Hoek, 2007; Tap et al., 2010). The first state 
results in a phenotype closely resembling primary human melanocytes, while the second 
results in a phenotype resembling neuronal stem cells (Hoek, 2007; Tap et al., 2010). Further, 
melanoma cells with a proliferative phenotype tend to be in a melanocytic differentiation 
state, while cells which acquire an invasive phenotype tend to dedifferentiate into a 
neuronal state. Several studies have demonstrated that melanoma has the ability to switch 
back-and-forth between these two phenotypes and/or differentiation states, triggered by 
factors such as microenvironmental conditions and therapeutic intervention (Hoek et al., 
2008; Hoek and Goding, 2010). The ability of melanoma cells to constantly switch 
phenotypes undoubtedly contributes to the resistance of melanoma to treatment. 
2.1.4 Cancer stem cells and melanoma 
Traditional chemotherapy operates largely under the premise that all cancer cells have equal 
malignant potential, with drug therapy focused on decreasing the population of cells within 
the tumor. Recently, studies looking at melanoma and other cancers have introduced the 
concept that certain populations within the tumor, often referred to as cancer stem cells 
(CSCs), have increased tumor initiating capabilities along with increased resistance to 
traditional chemotherapeutic approaches (Dou et al., 2007; Grichnik et al., 2006; Schatton et 
al., 2008). Consequently, the ability to identify, study and manipulate cells with the highest 
tumor-initiating capacity will be critical for developing effective therapeutic strategies. 
In the case of melanoma, the exact nature of CSCs remains controversial, with several 
putative CSC markers having been proposed in the literature (Zabierowski and Herlyn, 
2008). These markers include ABCB5 (Schatton et al., 2008), CD271/NGFR (Boiko et al., 
2010), and CD34 (Held et al., 2010). However, additional reports have demonstrated that 
tumor initiating capacity may actually be quite common among melanoma cells, and does 
not depend on the expression of any of the published putative melanoma CSC markers 
(Quintana et al., 2010; Quintana et al., 2008). In the context of cellular differentiation, studies 
have also  found that like other cancers, melanoma exhibits similarities to embryonic stem 
cells (Klein et al., 2007; Postovit et al., 2007).  The ability to correlate features of melanoma 
cells such as gene expression profiles with functional phenotypes such as tumor-initiating 
capacity (a hallmark of CSCs) will further delineate the role of cell fate in regulating 
melanoma progression. 
2.1.5 Tumor heterogeneity and plasticity 
While the cellular heterogeneity of tumors is a long-recognized phenomenon (Fidler, 1978), 
these recent studies highlight the variability within populations highlight regarding both 
gene signature and phenotypic plasticity. The concepts of phenotype switching and cancer 
stem cells in melanoma may both represent what happens within the tumor environment.  
Cancer stem cells may not be a fixed population, but rather a dynamically changing one 
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resulting from the phenotype switching of more “differentiated” cells in a tumor. This type 
of model could reconcile both sets of observations, and implies an inherent plasticity of 
melanoma cells that would undoubtedly complicate therapeutic efforts and potentially 
contribute to the variability seen with the use of cell surface markers to isolate CSC 
populations. While the use of the term differentiated in this model may again conjure up 
pre-conceptions that this population may be either more terminal/benign or less lethal in 
the long term, this assumption requires further experimental confirmation. 
2.2 The proliferative phenotype of melanoma cells 
Since cell fate and differentiation in the setting of cancer most closely parallels phenotype, 
this review will focus in particular on phenotypic characteristics that have been the center of 
efforts to understand melanoma at the molecular level. The first of the two major 
phenotypes expressed by malignant melanoma cells is the proliferative phenotype. As the 
name suggests, this phenotype is associated with a high rate of proliferation, as well as 
minimal invasive potential (Hoek et al., 2008; Hoek et al., 2006). Two key features of this 
group of cells help to account for their proliferative nature, including the activity of 
microphthalmia-associated transcription factor (MITF) (Levy et al., 2006) as well as the 
activity of the canonical Wnt/β-catenin pathway (Chien et al., 2009a). 
2.2.1 Microphthalmia transcription factor (MITF) 
MITF is a transcription factor that plays a critical role in the differentiation of melanoblasts 
from other cells derived from the neural crest (Levy et al., 2006), and severe mutations of MITF 
impede the embryonic development of melanocytes (Goding, 2000). It also plays a critical role 
in the normal functioning of differentiated primary melanocytes, regulating genes involved in 
the manufacture of melanosomes and melanin (Hornyak, 2006). This multi-tasking potential 
has been summarized using a proposed “rheostat model“ of MITF function (Carreira et al., 
2006; Hoek and Goding, 2010), which describes three different scenarios: MITF function in 
normal, differentiated melanocytes; MITF function in proliferative melanoma cells; and 
decreased MITF expression as seen in invasive melanoma cells.  
As previously mentioned, the primary role of MITF in a normally functioning melanocyte 
cell, where MITF expression is highest, is the regulation of genes involved in melanosome 
and melanin production (Lekmine et al., 2007; Levy et al., 2006). Some examples of the broad 
range of genes that affect pigmentation, whose expression is regulated by MITF, include 
melanocortin 1 receptor (MC1R), melanocortin 4 receptor (MC4R), tyrosinase (TYR) and 
melan-A (Lekmine et al., 2007; Levy et al., 2006). Other genes essential for normal 
melanocyte development, such as endothelin receptor type B (EDNRB) (Sato-Jin et al., 2008), 
p21cip1 (Carreira et al., 2005; Sestakova et al., 2010) and p16INK4 (Loercher et al., 2005), have 
also been shown to depend on MITF expression. Significantly, p21cip1 and p16INK4 are both 
regulators of the cell cycle, and are expressed when MITF levels are at their highest. 
As melanocytes acquire activating mutations in critical signalling pathways such as the 
MAPK pathway, the cellular effects of MITF change. Although the exact mechanism of this 
change is still not clear, it is primarily thought to be the result of altered post-translational 
modification of MITF, causing MITF to be targeted towards a different set of genes (Hoek 
and Goding, 2010). According to the rheostat model, overall MITF activity is also thought to 
be lower in malignant melanoma cells as compared to melanocytes (Hoek and Goding, 
2010). Consequently, MITF expression in this cell population results in suppression of 
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senescence and increased proliferation, as well as decreased invasiveness, both hallmarks of 
melanoma cells in the proliferative gene expression cluster.  
There have been many mechanisms proposed to help explain how MITF expression leads to 
increased proliferation of melanoma cells. For example, suppression of p27kip1, or cyclin-
dependent kinase inhibitor 1B (CDKN1B), is thought to be of primary importance in this 
process . The main function of p27kip1 is to impede cell cycle progression at G1. In melanoma 
cells with a proliferative phenotype, there is decreased p27kip1 expression (Carreira et al., 
2006). This is thought to be the result of increased expression of diaphanous-related formin 
DIA1, a protein which is upregulated by MITF and has a role in the regulation of a wide 
variety of cellular functions, including actin polymerization and E-cadherin organization. 
DIA1 in turn increases degradation of p27kip1 by S-phase kinase-associated protein 2 (SKP2), 
a gene which is regulated by DIA1 (Carreira et al., 2006). In addition, other genes 
upregulated by MITF in proliferative melanoma cells include BCL2 and CDK2 (Cheli et al., 
2010). While BCL2 upregulation imparts apoptotic resistance on melanoma cells, increased 
expression of cyclin-dependent kinase 2 results in cell cycle dysregulation and thus 
increased proliferation (Cheli et al., 2010).  
Besides increasing proliferation, MITF also contributes to the low invasive potential 
characteristic of melanoma cells in the “proliferative state”. Based on the results of Carreira et 
al., the ability of MITF to inhibit invasion is likely dependent on its DIA1-mediated regulation 
of the RHO/ROCK pathway, a known promoter of invasiveness (Carreira et al., 2006). MITF 
also appears to be a negative regulator of the Notch signalling cascade, which is itself a driver 
of invasive potential (Thurber et al., 2011). The frequent dysregulation of MITF by gene 
amplification in melanoma cells (Garraway et al., 2005) further highlights the critical nature of 
MITF in melanoma progression, and in the regulation of melanoma cell fate. 
2.2.2 Wnt/β-catenin signaling 
The Wnt/β-catenin signaling pathway represents a morphogenic pathway that is critical for 
development and almost always dysregulated in the context of cancers (Chien et al., 2009a) . 
Constitutive activation of the Wnt/β-catenin pathway is a common feature of many cancers, 
and increased activity of this pathway in general is a feature which distinguishes 
proliferative melanoma cells from invasive ones (Hoek et al., 2006). In the context of cellular 
differentiation and melanoma, which is neural crest-derived, Wnt/β-catenin signaling is 
particularly relevant since this pathway plays a pivotal role in regulating the differentiation 
of precursor cells into either neurons or melanocytes (Dorsky et al., 1998) .  
The key mediator of canonical Wnt/β-catenin pathway signalling is β-catenin, a protein 
whose degradation is inhibited upon Wnt ligand bidning, allowing its translocation to the 
nucleus where it regulates target gene expression (Chien et al., 2009a) . Wnt/β-catenin and 
MITF are intimately related in that β-catenin increases MITF expression (Dorsky et al., 
2000b), while MITF can interact with β-catenin in cultured malignant melanoma cells to alter 
its downstream gene-targeting (Widlund et al., 2002). Like MITF, Wnt/β-catenin signalling 
is critical to the normal embryonic development of melanocytes, so much so that the Wnt3a 
ligand is one of only three factors needed to stimulate the development of a pluripotent 
human embryonic stem cell into a mature melanocyte (Fang et al., 2006).  
The exact role of Wnt/β-catenin signaling in melanoma remains controversial, in part due to 
some differences in observed patient data and data obtained from murine models. Overall, 
increased activation of this pathway in approximately one-third of all melanomas is suggested 
by the presence of increased nuclear localization of β-catenin (Chien et al., 2009b), a surrogate 
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marker for Wnt/β-catenin activation. More importantly, the activation of Wnt/β-catenin 
signaling has been unexpectedly associated with improved patient survival (Bachmann et al., 
2005; Chien et al., 2009b). In addition, the presence of nuclear β-catenin in the majority of 
benign nevi (Bachmann et al., 2005; Kageshita et al., 2001; Maelandsmo et al., 2003) implicates a 
role for Wnt/β-catenin signaling in maintaining normal cellular homeostasis, and suggests 
that the dysregulaton of this pathway may contribute to the process of melanoma progression. 
The interpretation of these observations in patients is complicated by studies using a mouse 
model expressing a constitutively-active β-catenin mutant under the transcriptional control 
of a melanocyte-specific promoter. This transgenic mouse model suggests that increased 
Wnt/β-catenin signalling contributes to the initial immortalizaton of melanoma cells by 
inhbiting the expression of p16INK4a, a tumor suppressing protein which plays a key role in 
the induction of G1 cell cycle arrest in response to DNA damage (Delmas et al., 2007). 
Interestingly, although immortalization is often associated with proliferation, Delmas et al. 
show that in fact these two processes are effectively uncoupled during the process of 
malignant transformation in melanocytes (Delmas et al., 2007). However, despite facilitating 
the immortalization of melanocytes, the presence of a constitively-active β-catenin mutant 
was by itself not sufficient to generate spontaneous melanomas, which required 
concommitant activation of MAPK signaling through Nras mutation (Delmas et al., 2007).  
With regards to the issue of differentiation and questions surrounding the cell of origin for 
melanoma, the comparison of Wnt/β-catenin signaling in both human patients and mice 
raise two interesting points. First, melanomas from the mouse model appear to originate 
from the bulge region of the hair follicle, which is the proposed niche for melanocytic stem 
cells (Delmas et al., 2007); by contrast, most patient melanomas arise from interfollicular 
epidermis rather than from the hair follicle. Second, while these studies utilize a 
constitutively active mutant of β-catenin (Delmas et al., 2007), these types of activating 
mutations are quite rare in patient melanomas (Lucero et al., 2010), where Wnt/β-catenin 
activation is thought to result primarily from secreted Wnt ligand. Intuitively, the activation 
of signaling by secreted Wnt ligand is subject to modulation by extrinsic factors including 
endogenous inhibitors (i.e. DKK1, SFRPs) (Chien et al., 2009a), which would permit a model 
more akin the the MITF rheostat. Interestingly, the activation of Wnt/β-catenin signaling 
through the forced expression of WNT3A rather than a mutant β-catenin results in 
decreased proliferation in vitro and in vivo, correlating with the increased expression of 
genes associated with melanocyte differentiation (Chien et al., 2009b). 
2.3 The invasive phenotype of melanoma cells 
The second major gene expression signature of melanoma cells results in a phenotype 
characterized by a high degree of invasiveness and relatively lower rates of proliferation. 
Both MITF as well as canonical Wnt/β-catenin signalling are markedly downregulated in 
this population of cells, with a concomitant upregulation of a variety of pro-invasive 
mediators (Hoek et al., 2006). Notably, invasive melanoma cells are defined by genes 
suggestive of increased noncanonical WNT5A signalling, increased Notch1 signaling, 
upregulation of TGF-β and Brn-2 transcription factor as well as loss of the AP-2 
transcription factor, all of which are reviewed below.  
2.3.1 WNT5A and non-canonical Wnt signaling 
Whereas the canonical Wnt pathway is reliant on β-catenin signaling, the noncanonical Wnt 
pathway uses calcium-dependent mediators such as protein kinase C (PKC) to propagate 
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the signal of its primary extracellular ligand, WNT5A (Chien et al., 2009a). Normally, 
WNT5A signalling plays an important role in the regulation of cell fate, embryogenic 
patterning and cell motility (Chien et al., 2009a). In many forms of cancer, including colon, 
breast and liver cancer, WNT5A acts as a tumor suppressor (Chien and Moon, 2007). In the 
context of melanoma cell differentiation, which is assessed largely through gene signatures, 
the continued appearance of WNT5A as a major determinant of melanoma clusters in 
transcriptional profiling studies speaks to its likely importance as a genetic marker (Bittner 
et al., 2000; Hoek, 2007; Hoek et al., 2006; Weeraratna et al., 2004).  
Functionally, WNT5A is thought to contribute significantly to the invasive phenotype by 
regulating cellular migration, both through PKC and the re-distribution of cellular adhesion 
molecules (Dissanayake et al., 2007; Weeraratna et al., 2002; Witze et al., 2008). In addition, 
WNT5A signalling has been shown to inhibit the canonical Wnt/β-catenin pathway and 
consequently cause the downregulation of the downstream target genes of β-catenin (Chien 
et al., 2009b; Dissanayake et al., 2008), which may further contribute to its role in melanoma 
progression. The observation that WNT5A can be involved in the specification of 
dopaminergic neuronal cells (Castelo-Branco et al., 2003) and specification of axonal or 
synaptic function (Agalliu et al., 2009; Bodmer et al., 2009; Varela-Nallar et al., 2010) may 
also indicate a previously under-appreciated role of this pathway in the control of cellular 
differentiation. Conceivably, the role of WNT5A in neuronal cells may overlap with the 
phenotypic effects seen with WNT5A activation in melanoma cells, thereby contributing to 
whether these cells may display a phenotype that is neuronal as opposed to melanocyte-like. 
Alternatively, the expression of WNT5A in melanoma may simply be a reflection of cellular 
differentiation state, which would be consistent with transcriptional profiling studies where 
WNT5A is enriched in melanoma cells with a gene signature suggestive of neuroprogenitor 
cells (Tap et al., 2010). 
2.3.2 Notch signaling 
Another pathway implicated in melanoma is the Notch signaling cascade, which is one of 
the prototypical regulators of cell fate determination during embryonic development 
(Kopan and Ilagan, 2009). Like other primary transforming mutations in melanoma such as 
BRAF and NRAS, constitutive activation of the Notch1 receptor was in itself sufficient for 
the malignant transformation of human melanocytes (Pinnix et al., 2009). In fact, Notch1 
signaling is also required for β-catenin-induced proliferation in melanoma cells with a 
proliferative phenotype (Balint et al., 2005). However, the expression of Notch is negatively 
regulated by MITF, and thus its contribution to cellular phenotype is most pronounced in 
invasive melanoma cells where MITF is down-regulated (Thurber et al., 2011). Reports that 
these Notch effects in melanoma are mediated through regulation of the MAPK and PI3K-
Akt pathways (Liu et al., 2006a; Liu et al., 2006b) further highlight the convergence of critical 
pathways during melanoma progression.  
Like Wnt signaling, the Notch pathway plays a critical role in the specification of cell fate 
during neural crest development, making it particularly relevant to melanoma biology 
(Cornell and Eisen, 2005). During embryonic development, Notch signaling is thought to 
regulate both the specification of neural crest, as well as the subsequent determination of 
secondary cell fate through differentiation into glial-based lineages (Cornell and Eisen, 
2005). Engagement of Notch signaling can inhibit neurogenesis and neural differentiation, 
which may play some part in the role of this pathway in melanoma. Likewise in the context 
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of stem- and progenitor cells, Notch signaling can have varied roles in regulating either the 
maintenance of stem cell phenotype or the differentiation of stem cells into mature lineages 
(Liu et al., 2010). Understanding the interplay between Notch and other signaling pathways 
will be vital to effectively leveraging this important regulator of cellular differentiation for 
therapeutic benefit.  
2.3.3 Transforming growth factor-beta (TGFB) 
The morphogen-based Nodal signaling pathway, representing a subset of transforming 
growth factor β (TGFB) signaling pathways, was perhaps the initial pathway of interest in 
melanoma with regards to the concept of ‘differentiation therapy’ (Hardy et al., 2010; 
Postovit et al., 2008a; Postovit et al., 2008b; Strizzi et al., 2009). Like many of the other 
pathways that participate in melanoma biology, Nodal is a morphogen ligand involved the 
determination of cell fate during development. Melanoma is characterized by the presence 
of increased levels of Nodal ligand coinciding with decreased expression of the secreted 
Nodal antagonist Lefty (Postovit et al., 2008a). Typical benign nevi appear to express low 
levels of Nodal, although a subset of congenital nevi express levels of Nodal by 
immunohistochemistry that are comparable to what is observed in melanoma (Yu et al., 
2010). Analogous to its role in maintaining human embryonic stem cells in the 
undifferentiated state, Nodal signaling in melanoma is thought to regulate or facilitate the 
plasticity of tumor cells (Postovit et al., 2008a), thus eliciting considerable interest in the 
targeting of this pathway for therapeutic purposes.   
Overall, the role of TGFB in melanoma pathogenesis is complex, given the variability of its 
effects based on a cell’s stage of progression (Javelaud et al., 2008; Lasfar and Cohen-Solal, 
2010). Whereas normal human melanocytes are exquisitely sensitive to the anti-proliferative 
effects of TGF-β, resistance to this effect begins to develop as malignant transformation 
occurs. However, proliferative melanoma cells do retain sensitivity to TGF-β, and thus in 
this population of melanoma cells TGF-β actually acts as a tumor suppressor (Hoek et al., 
2006). Hoek et al. demonstrated that melanoma cells which clustered into the invasive, low 
MITF gene expression group also showed upregulation of many downstream targets of 
TGF-β (Hoek et al., 2006). Further, specific inhibition of the TGF-β signaling cascade via 
exogenous Smad7 significantly reduces the capacity of melanoma cells for anchorage-
independent growth, a characteristic intrinsic to metastatic potential (Javelaud et al., 2005). 
An important mechanism by which TGF-β signaling is able to increase invasive potential is 
likely its ability to decrease MITF expression, which results in upregulation of the pro-
invasive RHO/ROCK and Notch signaling cascades (Carreira et al., 2006; Thurber et al., 
2011). It also induces the expression of factors which inhibit canonical Wnt signaling (Hoek 
et al., 2006), promotes angiogenesis through factors such as VEGF, and has broad 
immunosuppressive effects which may contribute to the therapeutic resistance of TGF-β 
expressing tumor cells (Javelaud et al., 2008). 
A small but accumulating body of literature has also characterized the involvement in 
melanoma of bone morphogenic proteins (BMPs), which represent another subset of the 
TGFB superfamily (Hsu et al., 2005). Like TGFB, BMP7 can act in an autocrine fashion to 
inhibit melanoma cell growth (Hsu et al., 2008).  Interestingly, the upregulation of BMP7 
with melanoma progression coincides with upregulation of Noggin, an antagonist of BMP 
(Hsu et al., 2008). This finding parallels the observed acquisition of resistance to autocrine 
TGFB seen in melanoma cells compared to melanocytes (Krasagakis et al., 1999). In contrast, 
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others have reported that BMPs including BMP7 promote melanoma cell migration and 
invasion (Rothhammer et al., 2005), suggesting that the current model for how BMPs affect 
melanoma is still incomplete. The observation that nevi display relatively low levels of 
BMP4 and BMP7 may reflect that these cells retain sensitivity to these ligands (Rothhammer 
et al., 2005), and would be consistent with a potential oncogenic role for BMPs during 
melanoma progression.  
2.3.4 Brn-2 
Brn-2 is a POU domain transcription factor which regulates melanocytic growth (Cook and 
Sturm, 2008; Thomson et al., 1995), and in the setting of melanoma, is upregulated by both 
the MAPK and β-catenin signaling pathways (Goodall et al., 2004a; Goodall et al., 2004b). 
Increased expression of Brn-2 is a hallmark of invasive melanoma cells, and its activity 
contributes to this phenotype through a variety of different mechanisms. For one, Brn-2 is a 
potent repressor of MITF expression, and downregulation of Brn-2 during melanoblast 
differentiation to a mature melanocyte is necessary to ensure adequate expression of MITF 
(Goodall et al., 2004a). In invasive melanoma cells however, Brn-2 is upregulated, leading to 
MITF depletion and increased metastatic potential. Pinner et al. demonstrated that Brn-2 
upregulation is a key feature of invasive and metastatic melanoma cells through intravital 
imaging of GFP-tagged Brn-2 levels in melanoma (Pinner et al., 2009). The invasive and 
metastatic tumor cells also showed decreased pigmentation, a surrogate marker for de-
differentiation as a result of a Brn-2-induced decrease in MITF expression. Besides acting as 
a repressor of MITF expression, Brn-2 increases invasive potential through its role as an 
activator of the Notch pathway. With siRNA knockdown of Brn-2 in the A2058 melanoma 
cell line, there is a resultant decrease in the expression of several Notch1-related target genes 
(Thurber et al., 2011). Interestingly, Brn-2 is one of only three factors necessary to facilitate 
the conversion of mouse fibroblasts into functional neurons (Vierbuchen et al., 2010), 
demonstrating the importance of this pathway not only in melanocyte biology, but also in 
neuronal biology. This observation is not entirely surprising given close links 
developmentally between melanocytes and other neural crest-derived cell types. 
2.3.5 AP-2 
The activity of AP-2, a 52kDa transcription factor, is vital to the normal embryonic 
development of neural crest cells, and also appears to play an important role in the 
differentiation of adult cells (Bar-Eli, 2001; Tellez et al., 2003). In normal human 
melanocytes, AP-2 is responsible for the regulation of a host of normal cellular functions, 
including DNA repair, cell cycle arrest and cell adhesion (Zhuang et al., 2007). However, in 
melanoma cells, the loss of AP-2 is a prominent feature associated with a switch to an 
invasive phenotype (Braeuer et al., 2011). It appears that this downregulation is the result of 
the increased activity of cAMP-responsive element binding (CREB) protein, a common 
feature in melanoma progression due to dysregulation of the MAPK pathway (Melnikova et 
al., 2010). Melnikova et al. showed that activation of PKA-dependent CREB signaling down-
regulates AP-2 in invasive melanoma cells, while re-introduction of AP-2 into these cells 
restores a non-metastatic phenotype (Melnikova et al., 2010). By our definition, this effect of 
AP-2 would constitute forced differentiation, resulting in an altered cell fate. Further studies 
will be needed to address whether AP-2 and its regulation by PKA/CREB can utilized as a 
viable therapeutic strategy. 
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2.4 Classification of melanoma by states of differentiation 
2.4.1 Relating gene signatures to the differentiation of cell lineages 
Melanocytes develop from embryonic stem cells along two distinct lineages (Dorsky et al., 
2000a; Thomas and Erickson, 2008). The classical lineage involves migration of neural crest 
cells (NCC) from the dorsal aspect of the neural tube. These pluripotent NCC initially have 
the ability to differentiate into a wide variety of cell types, including smooth muscle cells, 
peripheral neurons and glia, as well as melanocytes (Dorsky et al., 2000a; Thomas and 
Erickson, 2008). Certain extrinsic factors are necessary in order to induce melanocytic 
differentiation of these stem cells, and several have been identified, including mast cell 
growth factor (MGF/KITLG), endothelin 3 (EDN3) and SOX10.  
Intriguingly, in the search for key intrinsic modulators of melanocytic differentiation, it 
appears as though one transcription factor acts as the universal regulator of this process: 
MITF (Goding, 2000). Mutations of the MITF gene cause neural crest cell dysfunction and 
marked impairment of normal pigmentation, as reflected in patients with a variant of 
Waardenburg Syndrome (Goding, 2000). Some typical markers of melanocytic 
differentiation include tyrosinase (TYR), melanoma antigen recognized by T-cells 1 (MART-
1) and transmembrane glycoprotein NMB (GPNMB).  
Not all melanocytes follow the same path of differentiation from the neural crest.  If the 
transcription factor HMX1 is expressed in the dorsal root ganglia, NCCs instead migrate 
along the ventral aspect of the dorsal root, and are induced to differentiate towards a 
neuronal phenotype (Adameyko et al., 2009; Krispin et al., 2010). These neuronal and glial 
cells are then directed to expanding branches of peripheral neurons throughout the body. 
Among this population of ventrally-derived neuronal cells is a group of pluripotent stem 
cells known as Schwann Cell Precursors (SCPs). Adameyko et al. demonstrated that 
although these cells are fully capable of differentiating into Schwann cells, SCPs are also 
capable of differentiating along a melanocytic lineage, under the influence of growth factors 
such as IGF-1 and PDGF (Adameyko et al., 2009). Melanocytes spawned from this neuronal 
lineage have a gene expression profile defined by a lack of MITF or Wnt/β-catenin 
influence, and thus lack expression of many melanocyte-specific genes (Tap et al., 2010). 
Thus, the transcriptional profile closely parallels (and in fact may represent) invasive or 
stem cell-like melanoma cells (Hoek et al., 2006).  
2.4.2 Melanoma gene signatures resembling melanocytes or neuronal precursors 
Analogous to the two distinct clusters of gene expression profiles representing proliferative 
and invasive subpopulations of melanoma cells discussed in this chapter until now, there is 
also a large body of research which has used transcriptional profiling studies to identify two 
major differentiation states of melanoma cells. These differentiation states have previously 
been classified by Tap et al. as either the differentiated melanocyte group (DMG), or the 
neuronal precursor group (NPG) (Tap et al., 2010). Based on our description of the two 
distinct lineages of melanocytes, the differentiation state of melanoma cells in the DMG 
resembles melanocytes of the classical lineage, while the differentiation state of melanoma in 
the NPG resembles melanocytes of a neuronal lineage. The existence of these two distinct 
melanoma differentiation states is in keeping with the cancer stem cell theory, which is 
quickly gaining acceptance within the cancer research community as the missing link in our 
understanding of phenomena such as metastasis and therapeutic resistance (Zabierowski 
and Herlyn, 2008). This theory proposes that every tumor is made up of cells in various 
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states of differentiation, with one subgroup made up of quickly dividing tumor cells which 
remain highly differentiated and another subgroup made up of tumor cells which take on a 
stem-like phenotype.  
In relation to melanoma, the melanocytic subgroup of cells, or DMG, represents a population 
of tumor cells which express many of the markers of a differentiated melanocyte. These 
markers include TYR, MART-1, GPNMB, endothelin receptor type B (EDNRB) and neurturin 
(Tap et al., 2010). Melanoma cells belonging to the DMG are increasingly being referred to as 
the fast-growing, differentiated counterparts to stem cell-like tumor initiating melanoma cells. 
As with melanocytes which develop from NCC via the classical lineage under strong SOX10 
influence, the well-differentiated population of melanoma tumor cells express a transcriptional 
profile which reflects the influence of MITF and Wnt/β-catenin signalling. Tap et al. postulate 
that melanoma cells belonging to the DMG develop as per the typical pattern of melanocyte 
development from the dorsal aspect of the neural tube (Tap et al., 2010). It would appear that  
melanoma cells in the DMG may in fact represent the same subgroup of highly proliferative, 
minimally invasive melanoma cells described by Hoek & Goding, and refered to as 
proliferative melanoma cells (Hoek and Goding, 2010; Tap et al., 2010).  
The existence of a distinct subpopulation of cells within malignant tumors which retain key 
stem cell-like properties such as the capacity for self-renewal and differentiation is a hallmark 
of the cancer stem cell theory, and indeed melanoma tumors do contain populations of de-
differentiated cells which resemble neuronal stem cells (Barnhill et al., 2004). Much like the 
neuronal melanocyte lineage which develops from NCC under the strong influence of the 
HMX1 transcription factor and a lack of SOX10 signalling, the stem-like NPG melanoma 
population expresses a relative lack of MITF and Wnt/β-catenin influence in its transrciptional 
profile (Tap et al., 2010). Instead, several cellular markers asociated with neuronal and not 
melanocytic cells are expressed, including neural crest nerve growth factor receptor CD271, 
glial fibrillary acidic protein (GFAP), neurofilament protein (NFP) and synaptophysin (Syn) 
(Boiko et al., 2010). Further, melanoma cells which express stem-like properties are highly 
invasive and minimally proliferative. Add to all of this the fact the transcriptional profile of the 
NPG reflects the strong influence of noncanonical WNT5A signalling, and we come to the 
reasonable conclusion that the de-differentiated population of neuronal melanoma cells 
identified by Tap et al. May in fact be equivalent to the invasive melanoma population 
described by Hoek & Goding (Hoek and Goding, 2010; Tap et al., 2010).  
2.5 Phenotype switching and tumor heterogeneity 
In contrast to the unidirectional genetic theory of melanoma progression is the fact that the 
proliferative transcriptional grouping is comprised of cell lines originating from primary 
tumors as well as from distant secondary metastases, while the invasive grouping 
predominantly contains pre-metastatic cells taken from the outer margins of a melanoma 
lesion, or metastatic melanoma cells collected during the actual process of intravascular 
migration (Eichhoff et al., 2010; Hoek et al., 2008). A Clark-like model of melanoma 
progression would instead predict that the proliferative grouping would be made up entirely 
of pre-metastatic cells, while the invasive grouping would contain mainly metastatic and post-
metastatic cells (Miller and Mihm, 2006). However, evidence derived from several in vivo 
studies instead suggests that melanoma cells have the ability to cycle from a predominantly 
proliferative to a predominantly invasive phenotype, based on such influences as the tumor 
microenvironment and pharmaceutical therapies (Hoek and Goding, 2010).  
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One compelling study in support of phenotype switching as a source of melanoma 
heterogeneity was conducted by Pinner et al., in which it was shown through the use 
intravital imaging of melanoma cells that highly motile, intravasated metastatic melanoma 
cells reverted back to their pre-metastatic, proliferative phenotype once seeding at the site of 
secondary tumor metastasis occurred (Pinner et al., 2009). Specifically, whereas melanoma 
cells in the primary tumor as well as the secondary metastatic tumor were shown to have a 
phenotype defined by low levels of the transcription factor Brn-2 and a high level of 
pigmentation, highly motile, actively metastasizing melanoma cells were shown to express a 
predominantly Brn-2-high/pigment-low phenotype (Pinner et al., 2009).  
In a patient-matched analysis of both a primary metastatic lesion and distant metastases, 
Eichhoff et al. demonstrated that, consistent with our description of proliferative and 
invasive melanoma phenotypes, cells in the primary and distant tumors expressed high 
levels of MITF and Melan-A, while cells in the "unstructured" regions of these tumors (areas 
from which metastatic cells are most likely to be derived) stained heavily for WNT5A and 
far less for Mitf and Melan-A (Eichhoff et al., 2010). Strikingly, this study also revealed late-
stage metastatic melanoma cells adopted phenotypes and morphologies nearly identical to 
early-phase cells, indicating that melanoma cells have significant plasticity with regards to 
their gene expression profile (Eichhoff et al., 2010).  
Lending further support to the existence of phenotype switching are the findings of Hoek et 
al., in which seed melanoma cells of either an exclusively proliferative or exclusively 
invasive phenotype were injected subcutaneously into immunocompromised mice (Hoek et 
al., 2008). Regardless of seed cell phenotype, the resultant tumors expressed both major gene 
signatures, and furthermore the signatures appeared to adhere to a strict geographic 
localization pattern within the tumor. Specifically, melanoma cells expressing a proliferative 
phenotype were predominantly found on the periphery of melanoma tumors, while the 
invasive melanoma cells were found within the core of the tumor. As the tumor invades to 
deeper levels of tissue, the cells within the tumor core are brought into contact with 
microenvironmental factors such as Nodal signaling proteins, which in turn drive 
melanoma invasion (Hoek et al., 2008).  
2.6 Cell fate as a determinant of therapeutic response 
2.6.1 The advent of targeted BRAF inhibitors for metastatic melanoma 
One of the most promising targeted molecular therapies currently under development are 
small-molecule targeted kinase inhibitors such as PLX4720 (Tsai et al., 2008) and PLX4032 
(Flaherty et al., 2010a; Halaban et al., 2010; Yang et al., 2010). This drug works by inhibiting 
the mutated form of BRAF, a key serine/threonine protein kinase in the mitogen-activated 
protein kinase (MAPK) pathway (Singh et al., 2008). Up to 40-60% of melanomas harbor 
activating BRAF mutations (Goel et al., 2006; Gorden et al., 2003; Greene et al., 2009), and of 
these mutations, most are the result of a single amino acid substitution in the activation loop 
of exon 15. The most common mutation is BRAFV600E mutation, which results in a 500-fold 
increase in kinase activity, and is the target of PLX4032 inhibition (Flaherty et al., 2010b). 
Indeed, the results of Phase I/II trials have been promising, with a demonstrated response 
rate of up to 80% (Roukos, 2011).  
Exposure to drugs such as PLX4720 or PLX4032 results in a variety of anti-melanoma effects 
through the inhibition of the MAPK pathway and more specifically by mitigating aberrant 
activation of extracellular signal-regulated kinase (ERK), a downstream target of BRAF. As a 
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result, the use of PLX4720 or PLX4032 in cells harbouring activating mutations of BRAF 
such as BRAFV600E demonstrate decreased levels of proliferation, impaired colony-forming 
capability and the induction of apoptosis (Tsai et al., 2008). Despite obvious excitement over 
the demonstrated response rate of PLX4032 thus far, talk of accelerated FDA approval and 
current Phase III clinical trials, questions still remain regarding the potential benefit of this 
drug on overall patient survival (Roukos, 2011).  
2.6.2 The impact of cell fate on response to targeted BRAF inhibition 
Despite producing startling initial results in some patients and achieving an overall 
response rate of around 80%, all melanomas sensitive to treatment with the V600 BRAF 
inhibitor PLX4032 eventually develop resistance, and some melanomas with the V600 BRAF 
mutation are resistant from the outset of treatment (Flaherty et al., 2010a). Thus, melanoma 
cells treated with PLX4032 make for an ideal model of mechanisms underlying the process 
of therapeutic resistance. 
Transcriptional profiling provides some insight into the role of cell fate and PLX4032 
resistance (Tap et al., 2010). In general, BRAF-mutant melanomas with a DMG 
(differentiated melanocyte group) gene expression signature had the least amount of 
resistance to growth inhibition by PLX4032, while melanoma cells with the NPG (neuronal 
precursor group) gene expression signature displayed the highest level of resistance to 
growth inhibition by PLX4032. However, the most interesting findings of this study stem 
from the characterization of initially sensitive cells which later acquired resistance. Contrary 
to the obvious conclusion that BRAF must have undergone further mutations thereby 
rendering PLX4032 unable to maintain its inhibitory effect, what investigators found instead 
was that the activity of several parallel signaling pathways was upregulated to compensate 
for the BRAF inhibition. Of note, levels of acquired drug resistance were highest in 
melanoma cells with mutated NRAS, a GTPase signaling molecule which allows for cross-
talk between the PI3K-AKT and MAPK pathways.  
In more general terms, it appears as though BRAF-mutated melanoma cells sensitive to 
PLX4032 uniformly revert to a less differentiated transcriptional profile resembling neuronal 
stem cells (Tap et al., 2010). Future studies will likely illuminate the exact role of cell fate in 
regulating the response to targeted BRAF inhibition. Understanding how the exact 
differentiation state of a cell (reflected by gene signature) affects phenotypes such as 
dependence on MAPK signaling, drug metabolism, and susceptibility to apoptosis will 
provide the foundation for developing therapies aimed at manipulating cell fate to 
therapeutic advantage. 
3. Conclusion 
Recent developments in our understanding of melanoma are particularly interesting with 
regards to thinking about forced differentiation as a potential therapeutic approach. Can we 
employ strong morphogen pathways to forcibly alter or refine melanoma cell fate in a 
manner that renders them more susceptible to therapies like targeted BRAF inhibition?  Are 
morphogen pathways able to act as a ‘master override’ within a large tumor cell population 
to effectively decrease the heterogeneity that arises from dynamic phenotype switching?  Is 
there a “differentiated” cancer cell state that is truly more benign and manageable compared 
to a parallel “undifferentiated” state?   
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Fig. 1. A summary of cell fate and differentiation in melanoma. This model attempts to 
reconcile findings in the literature regarding cell fate and differentiation. In the middle, 
melanoma cells are shown transitioning dynamically between two states: 1) a 
neuroprogenitor-like state (left) highlighted by gene signatures enriched for inhibitors of 
Wnt/β-catenin signaling such as WNT5A and DKK1; and 2) a more melanocyte-like state 
(right) exhibiting a gene signature consistent with active Wnt/β-catenin signaling, and 
reflecting increased expression of melanocytic markers. Note that the continued exposure of 
cells to PLX4032 can promote the development of cells with largely a neuronal or invasive 
signature (left). The increased survival denoted on the right side (upper part of panel) 
reflects the clinical observation that increased Wnt/β-catenin signaling correlates with 
increased patient survival (Bachmann et al., 2005; Chien et al., 2009b).  
Our traditional understanding of melanoma progression was based on the presumption that 
once a melanocyte acquired malignant potential, the constant accumulation of novel 
mutations conferred a progressively more aggressive phenotype as well as an increasing 
survival advantage to newly generated cancer cells. While it is true that key mutations such 
as the BRAF mutation targeted by PLX4032 are critical to melanoma pathogenesis, the 
sequence of intracellular events underlying the processes of tumor proliferation and 
metastasis in melanoma is far more dynamic than previously thought.  
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The recent characterization of distinct gene expression signatures in melanoma challenges 
our traditional model of melanoma progression. For one, two discreet transcriptional 
profiles would not be predicted by this model. Instead, we would expect a continuous 
spectrum of signatures representing the accumulation of new genetic mutations as 
melanoma became more aggressive. Secondly, we would expect that the transcriptional 
profiles of melanoma cells from secondary metastatic sites would bear less resemblance to 
cells in the primary tumor. Instead, proliferative melanoma cells from both primary and 
secondary sites are virtually identical, while the majority of invading and metastasizing 
melanoma cells express an invasive gene signature. Consequently, cell fate and the process 
of cellular differentiation are important for understanding the plasticity of melanoma cells 
and developing effective treatment strategies with durable long-term results. 
4. Acknowledgment  
A.J.C. is funded by a K08 Mentored Career Development Award from the NIH/NCI. This 
review was an attempt to summarize a broad and rapidly evolving field of research, and as 
is often the case with such ambitious undertakings, we were unable to include a 
comprehensive list of studies for this work. We apologize in advance for any unintended 
oversights that may have occurred. The authors would also like to thank Mr. Patrick O’Lin 
for editorial assistance during the preparation of this manuscript, and Mr. Ian A. Marsman 
for his assistance with mediating our international collaboration. 
5. References  
Adameyko, I., Lallemend, F., Aquino, J.B., Pereira, J.A., Topilko, P., Muller, T., Fritz, N., 
Beljajeva, A., Mochii, M., Liste, I., et al. (2009). Schwann cell precursors from nerve 
innervation are a cellular origin of melanocytes in skin. Cell 139, 366-379. 
Agalliu, D., Takada, S., Agalliu, I., McMahon, A.P., and Jessell, T.M. (2009). Motor neurons 
with axial muscle projections specified by Wnt4/5 signaling. Neuron 61, 708-720. 
Bachmann, I.M., Straume, O., Puntervoll, H.E., Kalvenes, M.B., and Akslen, L.A. (2005). 
Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of 
melanocytic tumors and prognosis in cutaneous melanoma. Clin Cancer Res 11, 
8606-8614. 
Balint, K., Xiao, M., Pinnix, C.C., Soma, A., Veres, I., Juhasz, I., Brown, E.J., Capobianco, A.J., 
Herlyn, M., and Liu, Z.J. (2005). Activation of Notch1 signaling is required for beta-
catenin-mediated human primary melanoma progression. J Clin Invest 115, 3166-
3176. 
Bar-Eli, M. (2001). Gene regulation in melanoma progression by the AP-2 transcription 
factor. Pigment Cell Res 14, 78-85. 
Barnhill, R., Piepkorn, M., and Busam, K.J. (2004). Pathology of melanocytic nevi and 
malignant melanoma (New York, Springer-Verlag). 
Bittner, M., Meltzer, P., Chen, Y., Jiang, Y., Seftor, E., Hendrix, M., Radmacher, M., Simon, 
R., Yakhini, Z., Ben-Dor, A., et al. (2000). Molecular classification of cutaneous 
malignant melanoma by gene expression profiling. Nature 406, 536-540. 
Bodmer, D., Levine-Wilkinson, S., Richmond, A., Hirsh, S., and Kuruvilla, R. (2009). Wnt5a 
mediates nerve growth factor-dependent axonal branching and growth in 
developing sympathetic neurons. J Neurosci 29, 7569-7581. 
www.intechopen.com
 The Role of Cellular Differentiation and Cell Fate in Malignant Melanoma 
 
303 
Boiko, A.D., Razorenova, O.V., van de Rijn, M., Swetter, S.M., Johnson, D.L., Ly, D.P., Butler, 
P.D., Yang, G.P., Joshua, B., Kaplan, M.J., et al. (2010). Human melanoma-initiating 
cells express neural crest nerve growth factor receptor CD271. Nature 466, 133-137. 
Braeuer, R.R., Zigler, M., Villares, G.J., Dobroff, A.S., and Bar-Eli, M. (2011). Transcriptional 
control of melanoma metastasis: The importance of the tumor microenvironment. 
Semin Cancer Biol 21, 83-88. 
Carreira, S., Goodall, J., Aksan, I., La Rocca, S.A., Galibert, M.D., Denat, L., Larue, L., and 
Goding, C.R. (2005). Mitf cooperates with Rb1 and activates p21Cip1 expression to 
regulate cell cycle progression. Nature 433, 764-769. 
Carreira, S., Goodall, J., Denat, L., Rodriguez, M., Nuciforo, P., Hoek, K.S., Testori, A., Larue, 
L., and Goding, C.R. (2006). Mitf regulation of Dia1 controls melanoma 
proliferation and invasiveness. Genes Dev 20, 3426-3439. 
Castelo-Branco, G., Wagner, J., Rodriguez, F.J., Kele, J., Sousa, K., Rawal, N., Pasolli, H.A., 
Fuchs, E., Kitajewski, J., and Arenas, E. (2003). Differential regulation of midbrain 
dopaminergic neuron development by Wnt-1, Wnt-3a, and Wnt-5a. Proc Natl Acad 
Sci U S A 100, 12747-12752. 
Cheli, Y., Ohanna, M., Ballotti, R., and Bertolotto, C. (2010). Fifteen-year quest for 
microphthalmia-associated transcription factor target genes. Pigment Cell 
Melanoma Res 23, 27-40. 
Chien, A.J., Conrad, W.H., and Moon, R.T. (2009a). A Wnt survival guide: from flies to 
human disease. J Invest Dermatol 129, 1614-1627. 
Chien, A.J., and Moon, R.T. (2007). WNTS and WNT receptors as therapeutic tools and 
targets in human disease processes. Front Biosci 12, 448-457. 
Chien, A.J., Moore, E.C., Lonsdorf, A.S., Kulikauskas, R.M., Rothberg, B.G., Berger, A.J., 
Major, M.B., Hwang, S.T., Rimm, D.L., and Moon, R.T. (2009b). Activated 
Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation 
in patient tumors and a murine melanoma model. Proc Natl Acad Sci U S A 106, 
1193-1198. 
Cook, A.L., and Sturm, R.A. (2008). POU domain transcription factors: BRN2 as a regulator of 
melanocytic growth and tumourigenesis. Pigment Cell Melanoma Res 21, 611-626. 
Cornell, R.A., and Eisen, J.S. (2005). Notch in the pathway: the roles of Notch signaling in 
neural crest development. Semin Cell Dev Biol 16, 663-672. 
Delmas, V., Beermann, F., Martinozzi, S., Carreira, S., Ackermann, J., Kumasaka, M., Denat, 
L., Goodall, J., Luciani, F., Viros, A., et al. (2007). Beta-catenin induces 
immortalization of melanocytes by suppressing p16INK4a expression and 
cooperates with N-Ras in melanoma development. Genes Dev 21, 2923-2935. 
Dissanayake, S.K., Olkhanud, P.B., O'Connell, M.P., Carter, A., French, A.D., Camilli, T.C., 
Emeche, C.D., Hewitt, K.J., Rosenthal, D.T., Leotlela, P.D., et al. (2008). Wnt5A 
regulates expression of tumor-associated antigens in melanoma via changes in 
signal transducers and activators of transcription 3 phosphorylation. Cancer Res 68, 
10205-10214. 
Dissanayake, S.K., Wade, M., Johnson, C.E., O'Connell, M.P., Leotlela, P.D., French, A.D., 
Shah, K.V., Hewitt, K.J., Rosenthal, D.T., Indig, F.E., et al. (2007). The 
Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the 
inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal 
transition. J Biol Chem 282, 17259-17271. 
Dorsky, R.I., Moon, R.T., and Raible, D.W. (1998). Control of neural crest cell fate by the Wnt 
signalling pathway. Nature 396, 370-373. 
www.intechopen.com
 Research on Melanoma: A Glimpse into Current Directions and Future Trends 
 
304 
Dorsky, R.I., Moon, R.T., and Raible, D.W. (2000a). Environmental signals and cell fate 
specification in premigratory neural crest. Bioessays 22, 708-716. 
Dorsky, R.I., Raible, D.W., and Moon, R.T. (2000b). Direct regulation of nacre, a zebrafish 
MITF homolog required for pigment cell formation, by the Wnt pathway. Genes 
Dev 14, 158-162. 
Dou, J., Pan, M., Wen, P., Li, Y., Tang, Q., Chu, L., Zhao, F., Jiang, C., Hu, W., Hu, K., et al. 
(2007). Isolation and identification of cancer stem-like cells from murine melanoma 
cell lines. Cell Mol Immunol 4, 467-472. 
Dupin, E., Glavieux, C., Vaigot, P., and Le Douarin, N.M. (2000). Endothelin 3 induces the 
reversion of melanocytes to glia through a neural crest-derived glial-melanocytic 
progenitor. Proc Natl Acad Sci U S A 97, 7882-7887. 
Dupin, E., Real, C., Glavieux-Pardanaud, C., Vaigot, P., and Le Douarin, N.M. (2003). 
Reversal of developmental restrictions in neural crest lineages: transition from 
Schwann cells to glial-melanocytic precursors in vitro. Proc Natl Acad Sci U S A 
100, 5229-5233. 
Eichhoff, O.M., Zipser, M.C., Xu, M., Weeraratna, A.T., Mihic, D., Dummer, R., and Hoek, 
K.S. (2010). The immunohistochemistry of invasive and proliferative phenotype 
switching in melanoma: a case report. Melanoma Res 20, 349-355. 
Fang, D., Leishear, K., Nguyen, T.K., Finko, R., Cai, K., Fukunaga, M., Li, L., Brafford, P.A., 
Kulp, A.N., Xu, X., et al. (2006). Defining the conditions for the generation of 
melanocytes from human embryonic stem cells. Stem Cells 24, 1668-1677. 
Fidler, I.J. (1978). Tumor heterogeneity and the biology of cancer invasion and metastasis. 
Cancer Res 38, 2651-2660. 
Flaherty, K., Puzanov, I., Kim, K., Ribas, A., McArthur, G.A., Sosman, J.A., O'Dwyer, P., Lee, 
R., Grippo, J.F., Nolop, K., et al. (2010a). Inhibition of mutated, activated BRAF in 
metastatic melanoma. N Engl J Med 363, 809-819. 
Flaherty, K.T., Hodi, F.S., and Bastian, B.C. (2010b). Mutation-driven drug development in 
melanoma. Curr Opin Oncol 22, 178-183. 
Garraway, L.A., Widlund, H.R., Rubin, M.A., Getz, G., Berger, A.J., Ramaswamy, S., 
Beroukhim, R., Milner, D.A., Granter, S.R., Du, J., et al. (2005). Integrative genomic 
analyses identify MITF as a lineage survival oncogene amplified in malignant 
melanoma. Nature 436, 117-122. 
Goding, C.R. (2000). Mitf from neural crest to melanoma: signal transduction and 
transcription in the melanocyte lineage. Genes Dev 14, 1712-1728. 
Goel, V.K., Lazar, A.J., Warneke, C.L., Redston, M.S., and Haluska, F.G. (2006). Examination 
of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest 
Dermatol 126, 154-160. 
Goodall, J., Martinozzi, S., Dexter, T.J., Champeval, D., Carreira, S., Larue, L., and Goding, 
C.R. (2004a). Brn-2 expression controls melanoma proliferation and is directly 
regulated by beta-catenin. Mol Cell Biol 24, 2915-2922. 
Goodall, J., Wellbrock, C., Dexter, T.J., Roberts, K., Marais, R., and Goding, C.R. (2004b). The 
Brn-2 transcription factor links activated BRAF to melanoma proliferation. Mol Cell 
Biol 24, 2923-2931. 
Gorden, A., Osman, I., Gai, W., He, D., Huang, W., Davidson, A., Houghton, A.N., Busam, 
K., and Polsky, D. (2003). Analysis of BRAF and N-RAS mutations in metastatic 
melanoma tissues. Cancer Res 63, 3955-3957. 
www.intechopen.com
 The Role of Cellular Differentiation and Cell Fate in Malignant Melanoma 
 
305 
Greene, V.R., Johnson, M.M., Grimm, E.A., and Ellerhorst, J.A. (2009). Frequencies of NRAS 
and BRAF mutations increase from the radial to the vertical growth phase in 
cutaneous melanoma. J Invest Dermatol 129, 1483-1488. 
Grichnik, J.M., Burch, J.A., Schulteis, R.D., Shan, S., Liu, J., Darrow, T.L., Vervaert, C.E., and 
Seigler, H.F. (2006). Melanoma, a tumor based on a mutant stem cell? J Invest 
Dermatol 126, 142-153. 
Halaban, R., Zhang, W., Bacchiocchi, A., Cheng, E., Parisi, F., Ariyan, S., Krauthammer, M., 
McCusker, J.P., Kluger, Y., and Sznol, M. (2010). PLX4032, a selective BRAF(V600E) 
kinase inhibitor, activates the ERK pathway and enhances cell migration and 
proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res 23, 190-200. 
Hardy, K.M., Kirschmann, D.A., Seftor, E.A., Margaryan, N.V., Postovit, L.M., Strizzi, L., 
and Hendrix, M.J. (2010). Regulation of the embryonic morphogen Nodal by 
Notch4 facilitates manifestation of the aggressive melanoma phenotype. Cancer Res 
70, 10340-10350. 
Held, M.A., Curley, D.P., Dankort, D., McMahon, M., Muthusamy, V., and Bosenberg, M.W. 
(2010). Characterization of melanoma cells capable of propagating tumors from a 
single cell. Cancer Res 70, 388-397. 
Hoek, K.S. (2007). DNA microarray analyses of melanoma gene expression: a decade in the 
mines. Pigment Cell Res 20, 466-484. 
Hoek, K.S., Eichhoff, O.M., Schlegel, N.C., Dobbeling, U., Kobert, N., Schaerer, L., Hemmi, 
S., and Dummer, R. (2008). In vivo switching of human melanoma cells between 
proliferative and invasive states. Cancer Res 68, 650-656. 
Hoek, K.S., and Goding, C.R. (2010). Cancer stem cells versus phenotype-switching in 
melanoma. Pigment Cell Melanoma Res 23, 746-759. 
Hoek, K.S., Schlegel, N.C., Brafford, P., Sucker, A., Ugurel, S., Kumar, R., Weber, B.L., 
Nathanson, K.L., Phillips, D.J., Herlyn, M., et al. (2006). Metastatic potential of 
melanomas defined by specific gene expression profiles with no BRAF signature. 
Pigment Cell Res 19, 290-302. 
Hsu, M.Y., Rovinsky, S., Penmatcha, S., Herlyn, M., and Muirhead, D. (2005). Bone 
morphogenetic proteins in melanoma: angel or devil? Cancer Metastasis Rev 24, 
251-263. 
Hsu, M.Y., Rovinsky, S.A., Lai, C.Y., Qasem, S., Liu, X., How, J., Engelhardt, J.F., and 
Murphy, G.F. (2008). Aggressive melanoma cells escape from BMP7-mediated 
autocrine growth inhibition through coordinated Noggin upregulation. Lab Invest 
88, 842-855. 
Javelaud, D., Alexaki, V.I., and Mauviel, A. (2008). Transforming growth factor-beta in 
cutaneous melanoma. Pigment Cell Melanoma Res 21, 123-132. 
Javelaud, D., Delmas, V., Moller, M., Sextius, P., Andre, J., Menashi, S., Larue, L., and 
Mauviel, A. (2005). Stable overexpression of Smad7 in human melanoma cells 
inhibits their tumorigenicity in vitro and in vivo. Oncogene 24, 7624-7629. 
Kageshita, T., Hamby, C.V., Ishihara, T., Matsumoto, K., Saida, T., and Ono, T. (2001). Loss 
of beta-catenin expression associated with disease progression in malignant 
melanoma. Br J Dermatol 145, 210-216. 
Klein, W.M., Wu, B.P., Zhao, S., Wu, H., Klein-Szanto, A.J., and Tahan, S.R. (2007). Increased 
expression of stem cell markers in malignant melanoma. Mod Pathol 20, 102-107. 
Kopan, R., and Ilagan, M.X. (2009). The canonical Notch signaling pathway: unfolding the 
activation mechanism. Cell 137, 216-233. 
www.intechopen.com
 Research on Melanoma: A Glimpse into Current Directions and Future Trends 
 
306 
Krasagakis, K., Kruger-Krasagakes, S., Fimmel, S., Eberle, J., Tholke, D., von der Ohe, M., 
Mansmann, U., and Orfanos, C.E. (1999). Desensitization of melanoma cells to 
autocrine TGF-beta isoforms. J Cell Physiol 178, 179-187. 
Krispin, S., Nitzan, E., and Kalcheim, C. (2010). The dorsal neural tube: a dynamic setting for 
cell fate decisions. Dev Neurobiol 70, 796-812. 
Lasfar, A., and Cohen-Solal, K.A. (2010). Resistance to transforming growth factor beta-
mediated tumor suppression in melanoma: are multiple mechanisms in place? 
Carcinogenesis 31, 1710-1717. 
Lekmine, F., Chang, C.K., Sethakorn, N., Das Gupta, T.K., and Salti, G.I. (2007). Role of 
microphthalmia transcription factor (Mitf) in melanoma differentiation. Biochem 
Biophys Res Commun 354, 830-835. 
Lens, M.B., and Dawes, M. (2004). Global perspectives of contemporary epidemiological 
trends of cutaneous malignant melanoma. Br J Dermatol 150, 179-185. 
Levy, C., Khaled, M., and Fisher, D.E. (2006). MITF: master regulator of melanocyte 
development and melanoma oncogene. Trends Mol Med 12, 406-414. 
Liu, J., Sato, C., Cerletti, M., and Wagers, A. (2010). Notch signaling in the regulation of stem 
cell self-renewal and differentiation. Curr Top Dev Biol 92, 367-409. 
Liu, Z.J., Xiao, M., Balint, K., Smalley, K.S., Brafford, P., Qiu, R., Pinnix, C.C., Li, X., and 
Herlyn, M. (2006a). Notch1 signaling promotes primary melanoma progression by 
activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt 
pathways and up-regulating N-cadherin expression. Cancer Res 66, 4182-4190. 
Liu, Z.J., Xiao, M., Balint, K., Soma, A., Pinnix, C.C., Capobianco, A.J., Velazquez, O.C., and 
Herlyn, M. (2006b). Inhibition of endothelial cell proliferation by Notch1 signaling 
is mediated by repressing MAPK and PI3K/Akt pathways and requires MAML1. 
Faseb J 20, 1009-1011. 
Loercher, A.E., Tank, E.M., Delston, R.B., and Harbour, J.W. (2005). MITF links 
differentiation with cell cycle arrest in melanocytes by transcriptional activation of 
INK4A. J Cell Biol 168, 35-40. 
Lucero, O.M., Dawson, D.W., Moon, R.T., and Chien, A.J. (2010). A re-evaluation of the 
"oncogenic" nature of Wnt/beta-catenin signaling in melanoma and other cancers. 
Curr Oncol Rep 12, 314-318. 
Maelandsmo, G.M., Holm, R., Nesland, J.M., Fodstad, O., and Florenes, V.A. (2003). 
Reduced beta-catenin expression in the cytoplasm of advanced-stage superficial 
spreading malignant melanoma. Clin Cancer Res 9, 3383-3388. 
Melnikova, V.O., Dobroff, A.S., Zigler, M., Villares, G.J., Braeuer, R.R., Wang, H., Huang, L., 
and Bar-Eli, M. (2010). CREB inhibits AP-2alpha expression to regulate the 
malignant phenotype of melanoma. PLoS One 5, e12452. 
Miller, A.J., and Mihm, M.C., Jr. (2006). Melanoma. N Engl J Med 355, 51-65. 
Pinner, S., Jordan, P., Sharrock, K., Bazley, L., Collinson, L., Marais, R., Bonvin, E., Goding, 
C., and Sahai, E. (2009). Intravital imaging reveals transient changes in pigment 
production and Brn2 expression during metastatic melanoma dissemination. 
Cancer Res 69, 7969-7977. 
Pinnix, C.C., Lee, J.T., Liu, Z.J., McDaid, R., Balint, K., Beverly, L.J., Brafford, P.A., Xiao, M., 
Himes, B., Zabierowski, S.E., et al. (2009). Active Notch1 confers a transformed 
phenotype to primary human melanocytes. Cancer Res 69, 5312-5320. 
Postovit, L.M., Costa, F.F., Bischof, J.M., Seftor, E.A., Wen, B., Seftor, R.E., Feinberg, A.P., 
Soares, M.B., and Hendrix, M.J. (2007). The commonality of plasticity underlying 
multipotent tumor cells and embryonic stem cells. J Cell Biochem 101, 908-917. 
www.intechopen.com
 The Role of Cellular Differentiation and Cell Fate in Malignant Melanoma 
 
307 
Postovit, L.M., Margaryan, N.V., Seftor, E.A., and Hendrix, M.J. (2008a). Role of nodal 
signaling and the microenvironment underlying melanoma plasticity. Pigment Cell 
Melanoma Res 21, 348-357. 
Postovit, L.M., Margaryan, N.V., Seftor, E.A., Kirschmann, D.A., Lipavsky, A., Wheaton, 
W.W., Abbott, D.E., Seftor, R.E., and Hendrix, M.J. (2008b). Human embryonic stem 
cell microenvironment suppresses the tumorigenic phenotype of aggressive cancer 
cells. Proc Natl Acad Sci U S A 105, 4329-4334. 
Quintana, E., Shackleton, M., Foster, H.R., Fullen, D.R., Sabel, M.S., Johnson, T.M., and 
Morrison, S.J. (2010). Phenotypic heterogeneity among tumorigenic melanoma cells 
from patients that is reversible and not hierarchically organized. Cancer Cell 18, 
510-523. 
Quintana, E., Shackleton, M., Sabel, M.S., Fullen, D.R., Johnson, T.M., and Morrison, S.J. 
(2008). Efficient tumour formation by single human melanoma cells. Nature 456, 
593-598. 
Rothhammer, T., Poser, I., Soncin, F., Bataille, F., Moser, M., and Bosserhoff, A.K. (2005). 
Bone morphogenic proteins are overexpressed in malignant melanoma and 
promote cell invasion and migration. Cancer Res 65, 448-456. 
Roukos, D.H. (2011). PLX4032 and melanoma: resistance, expectations and uncertainty. 
Expert Rev Anticancer Ther 11, 325-328. 
Sato-Jin, K., Nishimura, E.K., Akasaka, E., Huber, W., Nakano, H., Miller, A., Du, J., Wu, M., 
Hanada, K., Sawamura, D., et al. (2008). Epistatic connections between 
microphthalmia-associated transcription factor and endothelin signaling in 
Waardenburg syndrome and other pigmentary disorders. Faseb J 22, 1155-1168. 
Schatton, T., Murphy, G.F., Frank, N.Y., Yamaura, K., Waaga-Gasser, A.M., Gasser, M., 
Zhan, Q., Jordan, S., Duncan, L.M., Weishaupt, C., et al. (2008). Identification of cells 
initiating human melanomas. Nature 451, 345-349. 
Schmoeckel, C., Castro, C.E., and Braun-Falco, O. (1985). Nevoid malignant melanoma. Arch 
Dermatol Res 277, 362-369. 
Sestakova, B., Ondrusova, L., and Vachtenheim, J. (2010). Cell cycle inhibitor p21/ WAF1/ 
CIP1 as a cofactor of MITF expression in melanoma cells. Pigment Cell Melanoma 
Res 23, 238-251. 
Singh, M., Lin, J., Hocker, T.L., and Tsao, H. (2008). Genetics of melanoma tumorigenesis. Br 
J Dermatol 158, 15-21. 
Strizzi, L., Hardy, K.M., Seftor, E.A., Costa, F.F., Kirschmann, D.A., Seftor, R.E., Postovit, 
L.M., and Hendrix, M.J. (2009). Development and cancer: at the crossroads of Nodal 
and Notch signaling. Cancer Res 69, 7131-7134. 
Tap, W.D., Gong, K.W., Dering, J., Tseng, Y., Ginther, C., Pauletti, G., Glaspy, J.A., Essner, 
R., Bollag, G., Hirth, P., et al. (2010). Pharmacodynamic characterization of the 
efficacy signals due to selective BRAF inhibition with PLX4032 in malignant 
melanoma. Neoplasia 12, 637-649. 
Tellez, C., McCarty, M., Ruiz, M., and Bar-Eli, M. (2003). Loss of activator protein-2alpha 
results in overexpression of protease-activated receptor-1 and correlates with the 
malignant phenotype of human melanoma. J Biol Chem 278, 46632-46642. 
Thomas, A.J., and Erickson, C.A. (2008). The making of a melanocyte: the specification of 
melanoblasts from the neural crest. Pigment Cell Melanoma Res 21, 598-610. 
Thomson, J.A., Murphy, K., Baker, E., Sutherland, G.R., Parsons, P.G., Sturm, R.A., and 
Thomson, F. (1995). The brn-2 gene regulates the melanocytic phenotype and 
tumorigenic potential of human melanoma cells. Oncogene 11, 691-700. 
www.intechopen.com
 Research on Melanoma: A Glimpse into Current Directions and Future Trends 
 
308 
Thurber, A.E., Douglas, G., Sturm, E.C., Zabierowski, S.E., Smit, D.J., Ramakrishnan, S.N., 
Hacker, E., Leonard, J.H., Herlyn, M., and Sturm, R.A. (2011). Inverse expression 
states of the BRN2 and MITF transcription factors in melanoma spheres and 
tumour xenografts regulate the NOTCH pathway. Oncogene. 
Tsai, J., Lee, J.T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., 
Haass, N.K., et al. (2008). Discovery of a selective inhibitor of oncogenic B-Raf 
kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 105, 3041-3046. 
Tsao, H., Atkins, M.B., and Sober, A.J. (2004). Management of cutaneous melanoma. N Engl 
J Med 351, 998-1012. 
Varela-Nallar, L., Alfaro, I.E., Serrano, F.G., Parodi, J., and Inestrosa, N.C. (2010). Wingless-
type family member 5A (Wnt-5a) stimulates synaptic differentiation and function 
of glutamatergic synapses. Proc Natl Acad Sci U S A 107, 21164-21169. 
Vierbuchen, T., Ostermeier, A., Pang, Z.P., Kokubu, Y., Sudhof, T.C., and Wernig, M. (2010). 
Direct conversion of fibroblasts to functional neurons by defined factors. Nature 
463, 1035-1041. 
Weeraratna, A.T., Becker, D., Carr, K.M., Duray, P.H., Rosenblatt, K.P., Yang, S., Chen, Y., 
Bittner, M., Strausberg, R.L., Riggins, G.J., et al. (2004). Generation and analysis of 
melanoma SAGE libraries: SAGE advice on the melanoma transcriptome. 
Oncogene 23, 2264-2274. 
Weeraratna, A.T., Jiang, Y., Hostetter, G., Rosenblatt, K., Duray, P., Bittner, M., and Trent, 
J.M. (2002). Wnt5a signaling directly affects cell motility and invasion of metastatic 
melanoma. Cancer Cell 1, 279-288. 
Widlund, H.R., Horstmann, M.A., Price, E.R., Cui, J., Lessnick, S.L., Wu, M., He, X., and 
Fisher, D.E. (2002). Beta-catenin-induced melanoma growth requires the 
downstream target Microphthalmia-associated transcription factor. J Cell Biol 158, 
1079-1087. 
Winkelmann, R.K., and Rocha, G. (1962). The dermal nevus and statistics. An evaluation of 
1,200 pigmented lesions. Arch Dermatol 86, 310-315. 
Witze, E.S., Litman, E.S., Argast, G.M., Moon, R.T., and Ahn, N.G. (2008). Wnt5a control of 
cell polarity and directional movement by polarized redistribution of adhesion 
receptors. Science 320, 365-369. 
Yang, H., Higgins, B., Kolinsky, K., Packman, K., Go, Z., Iyer, R., Kolis, S., Zhao, S., Lee, R., 
Grippo, J.F., et al. (2010). RG7204 (PLX4032), a selective BRAFV600E inhibitor, 
displays potent antitumor activity in preclinical melanoma models. Cancer Res 70, 
5518-5527. 
Yu, L., Harms, P.W., Pouryazdanparast, P., Kim, D.S., Ma, L., and Fullen, D.R. (2010). 
Expression of the embryonic morphogen Nodal in cutaneous melanocytic lesions. 
Mod Pathol 23, 1209-1214. 
Zabierowski, S.E., and Herlyn, M. (2008). Melanoma stem cells: the dark seed of melanoma. J 
Clin Oncol 26, 2890-2894. 
Zhuang, L., Lee, C.S., Scolyer, R.A., McCarthy, S.W., Zhang, X.D., Thompson, J.F., and 
Hersey, P. (2007). Mcl-1, Bcl-XL and Stat3 expression are associated with 
progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during 
progression of melanoma. Mod Pathol 20, 416-426. 
www.intechopen.com
Research on Melanoma - A Glimpse into Current Directions and
Future Trends
Edited by Prof. Mandi Murph
ISBN 978-953-307-293-7
Hard cover, 414 pages
Publisher InTech
Published online 12, September, 2011
Published in print edition September, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The book Research on Melanoma: A Glimpse into Current Directions and Future Trends, is divided into
sections to represent the most cutting-edge topics in melanoma from around the world. The emerging
epigenetics of disease, novel therapeutics under development and the molecular signaling aberrations are
explained in detail. Since there are a number of areas in which unknowns exist surrounding the complex
development of melanoma and its response to therapy, this book illuminates and comprehensively discusses
such aspects. It is relevant for teaching the novice researcher who wants to initiate projects in melanoma and
the more senior researcher seeking to polish their existing knowledge in this area. Many chapters include
visuals and illustrations designed to easily guide the reader through the ideas presented.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Paul Kuzel and Andy J. Chien (2011). The Role of Cellular Differentiation and Cell Fate in Malignant
Melanoma, Research on Melanoma - A Glimpse into Current Directions and Future Trends, Prof. Mandi Murph
(Ed.), ISBN: 978-953-307-293-7, InTech, Available from: http://www.intechopen.com/books/research-on-
melanoma-a-glimpse-into-current-directions-and-future-trends/the-role-of-cellular-differentiation-and-cell-fate-
in-malignant-melanoma
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
